ImmuPharma (LON:IMM) Shares Up 25.3% - Still a Buy?

Key Points

• ImmuPharma's stock price surged 25.3% on Monday, reaching a last traded value of GBX 17.51 ($0.24).
• The trading volume increased significantly, with approximately 65.6 million shares exchanged, marking a 677% rise from its average daily volume.
• ImmuPharma specializes in peptide-based therapeutics and reported negative earnings per share of GBX (0.38) for its last quarterly earnings.

ImmuPharma plc (LON:IMM - Get Free Report) shares rose 25.3% on Monday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). Approximately 65,638,188 shares were traded during trading, an increase of 677% from the average daily volume of 8,446,959 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Down 21.1%

The company has a market cap of £58.76 million, a price-to-earnings ratio of -1,321.12 and a beta of 1.53. The stock has a fifty day moving average price of GBX 3.68 and a two-hundred day moving average price of GBX 3.09.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.